results

Byrna Technologies Announces Preliminary Fiscal Second Quarter Record Revenues of $28.5 Million

Company Achieves 41% Year-Over-Year Growth Driven by Compact Launcher Rollout and Retail Expansion June 05, 2025 16:05 ET  | Source:…

8 months ago

Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer

46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an…

8 months ago

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant…

8 months ago

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1…

8 months ago

New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…

8 months ago

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of…

8 months ago

Suraj Estate Developers Reports Robust FY25 Performance with 33% Growth in Revenue and 48% Jump in PAT

MUMBAI, India, May 29, 2025 /PRNewswire/ -- Suraj Estate Developers Ltd. today announced its financial results for the fiscal year…

8 months ago